Literature DB >> 21035788

Reduced dorsal prefrontal gray matter after chronic ketamine use.

Yanhui Liao1, Jinsong Tang, Philip R Corlett, Xuyi Wang, Mei Yang, Hongxian Chen, Tieqiao Liu, Xiaogang Chen, Wei Hao, Paul C Fletcher.   

Abstract

BACKGROUND: Use of ketamine as a recreational drug is spreading rapidly among young people all over the world. Epidemiological studies have linked chronic ketamine use with a number of problems, including cognitive impairments, bladder dysfunction, and ketamine-related death. However, little is known about the long-term effects of ketamine use on brain structure and function.
METHODS: We used voxel based morphometry in conjunction with statistical parametric mapping on the structural magnetic resonance images of ketamine-dependent (n = 41) and drug-naive control individuals (n = 44) to assess differences in gray matter volume between the two groups.
RESULTS: We observed significant decreases in gray matter volume in bilateral frontal cortex (left superior frontal gyrus and right middle frontal gyrus) of ketamine users in comparison with control subjects (p < .05 corrected for multiple comparisons at cluster-level). Duration of ketamine use was negatively correlated with gray matter volume in bilateral frontal cortex, whereas the estimated total lifetime ketamine consumption was negatively correlated with gray matter volume in left superior frontal gyrus.
CONCLUSIONS: We have demonstrated a reduction in frontal gray matter volume in patients after chronic ketamine use. The link between frontal gray matter attenuation and the duration of ketamine use and cumulative doses of ketamine perhaps suggests a dose-dependent effect of long-term use of the drug. Our results have important connotations for the clinical picture that is likely to emerge with the growing recreational use of ketamine and is also relevant to the status of the drug as a model for schizophrenia.
Copyright © 2011 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21035788     DOI: 10.1016/j.biopsych.2010.08.030

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  34 in total

Review 1.  Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.

Authors:  Mark J Niciu; Ioline D Henter; David A Luckenbaugh; Carlos A Zarate; Dennis S Charney
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014       Impact factor: 13.820

Review 2.  Ketamine for chronic pain: risks and benefits.

Authors:  Marieke Niesters; Christian Martini; Albert Dahan
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

Review 3.  Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders?

Authors:  Gerard Sanacora; Alan F Schatzberg
Journal:  Neuropsychopharmacology       Date:  2014-09-26       Impact factor: 7.853

4.  Source memory in rats is impaired by an NMDA receptor antagonist but not by PSD95-nNOS protein-protein interaction inhibitors.

Authors:  Alexandra E Smith; Zhili Xu; Yvonne Y Lai; Pushkar M Kulkarni; Ganesh A Thakur; Andrea G Hohmann; Jonathon D Crystal
Journal:  Behav Brain Res       Date:  2016-02-22       Impact factor: 3.332

5.  Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression.

Authors:  Samuel T Wilkinson; DaShaun Wright; Madonna K Fasula; Lisa Fenton; Matthew Griepp; Robert B Ostroff; Gerard Sanacora
Journal:  Psychother Psychosom       Date:  2017-05-11       Impact factor: 17.659

6.  Juvenile exposure to ketamine causes delayed emergence of EEG abnormalities during adulthood in mice.

Authors:  R E Featherstone; L R Nagy; C G Hahn; S J Siegel
Journal:  Drug Alcohol Depend       Date:  2013-09-27       Impact factor: 4.492

7.  Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver.

Authors:  Scott A Schobel; Nashid H Chaudhury; Usman A Khan; Beatriz Paniagua; Martin A Styner; Iris Asllani; Benjamin P Inbar; Cheryl M Corcoran; Jeffrey A Lieberman; Holly Moore; Scott A Small
Journal:  Neuron       Date:  2013-04-10       Impact factor: 17.173

8.  Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.

Authors:  James W Murrough; Andrew M Perez; Sarah Pillemer; Jessica Stern; Michael K Parides; Marije aan het Rot; Katherine A Collins; Sanjay J Mathew; Dennis S Charney; Dan V Iosifescu
Journal:  Biol Psychiatry       Date:  2012-07-27       Impact factor: 13.382

9.  Effects of early ketamine exposure on cerebral gray matter volume and functional connectivity.

Authors:  Chia-Chun Hung; Yi-Hsuan Liu; Chu-Chung Huang; Cheng-Ying Chou; Chun-Ming Chen; Jeng-Ren Duann; Chiang-Shan R Li; Tony Szu-Hsien Lee; Ching-Po Lin
Journal:  Sci Rep       Date:  2020-09-23       Impact factor: 4.379

10.  Abnormalities in white matter microstructure associated with chronic ketamine use.

Authors:  R Edward Roberts; H Valerie Curran; Karl J Friston; Celia J A Morgan
Journal:  Neuropsychopharmacology       Date:  2013-08-09       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.